Bio Free Cash Flow Yield vs Pfcf Ratio Analysis

BPTH Stock

USD 0.77 0.03 3.75%

Bio Path financial indicator trend analysis is way more than just evaluating Bio Path Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Path Holdings is a good investment. Please check the relationship between Bio Path Free Cash Flow Yield and its Pfcf Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Free Cash Flow Yield vs Pfcf Ratio

Free Cash Flow Yield vs Pfcf Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Path Holdings Free Cash Flow Yield account and Pfcf Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Bio Path's Free Cash Flow Yield and Pfcf Ratio is -0.34. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Pfcf Ratio in the same time period over historical financial statements of Bio Path Holdings, assuming nothing else is changed. The correlation between historical values of Bio Path's Free Cash Flow Yield and Pfcf Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Bio Path Holdings are associated (or correlated) with its Pfcf Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pfcf Ratio has no effect on the direction of Free Cash Flow Yield i.e., Bio Path's Free Cash Flow Yield and Pfcf Ratio go up and down completely randomly.

Correlation Coefficient

-0.34

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Pfcf Ratio

Most indicators from Bio Path's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Path Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

The Bio Path's current Sales General And Administrative To Revenue is estimated to increase to 179.88, while Selling General Administrative is projected to decrease to under 2.4 M.

	2021	2022	2023	2024 (projected)
Net Interest Income	3K	33K	52K	32.5K
Interest Income	3K	33K	52K	31.0K

Net Interest Income Interest Income

Bio Path fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.08	0.28	0.2	0.99	0.52	-0.28	-0.99	-0.29	-0.06	0.99	-0.09	-0.42	0.99	-0.11	-0.07	-0.06	-0.15	0.4	0.45	0.12	0.36	1.0	0.2	-0.56	-0.15
Short Long Term Debt Total	0.08		-0.42	-0.56	0.13	0.12	-0.25	-0.11	0.68	-0.28	0.11	0.78	-0.18	0.11	0.92	0.24	-0.01	0.32	-0.6	-0.61	-0.36	-0.69	0.02	-0.82	0.01	0.54
Other Current Liab	0.28	-0.42		0.87	0.17	0.39	-0.52	-0.23	-0.79	0.24	0.23	-0.35	-0.01	0.23	-0.39	0.3	0.41	-0.07	0.53	0.79	0.8	0.71	0.3	0.59	-0.67	-0.32
Total Current Liabilities	0.2	-0.56	0.87		0.1	0.39	-0.46	-0.13	-0.94	0.67	0.13	-0.6	-0.12	0.13	-0.5	0.25	0.33	-0.24	0.71	0.91	0.76	0.83	0.24	0.72	-0.68	-0.61
Total Stockholder Equity	0.99	0.13	0.17	0.1		0.46	-0.24	-0.99	-0.21	-0.1	0.99	-0.06	-0.42	0.99	-0.07	-0.11	-0.18	-0.11	0.34	0.38	-0.01	0.28	0.99	0.15	-0.49	-0.13
Property Plant And Equipment Net	0.52	0.12	0.39	0.39	0.46		-0.26	-0.48	-0.38	0.23	0.49	-0.15	-0.38	0.49	-0.01	0.08	0.4	-0.49	0.29	0.44	0.48	0.45	0.52	0.09	-0.64	-0.48
Current Deferred Revenue	-0.28	-0.25	-0.52	-0.46	-0.24	-0.26		0.23	0.44	-0.28	-0.23	-0.28	0.04	-0.23	-0.26	-0.6	-0.16	-0.05	-0.24	-0.46	-0.34	-0.33	-0.26	-0.15	0.69	0.08
Net Debt	-0.99	-0.11	-0.23	-0.13	-0.99	-0.48	0.23		0.23	0.11	-1.0	0.09	0.45	-1.0	0.07	0.1	0.08	0.13	-0.3	-0.39	-0.08	-0.29	-0.99	-0.13	0.51	0.11
Retained Earnings	-0.29	0.68	-0.79	-0.94	-0.21	-0.38	0.44	0.23		-0.6	-0.23	0.67	0.06	-0.23	0.66	-0.17	-0.16	0.37	-0.8	-0.98	-0.63	-0.93	-0.34	-0.85	0.67	0.74
Accounts Payable	-0.06	-0.28	0.24	0.67	-0.1	0.23	-0.28	0.11	-0.6		-0.11	-0.52	-0.25	-0.11	-0.19	0.24	0.12	-0.3	0.51	0.55	0.34	0.51	-0.02	0.38	-0.41	-0.63
Cash	0.99	0.11	0.23	0.13	0.99	0.49	-0.23	-1.0	-0.23	-0.11		-0.1	-0.46	1.0	-0.08	-0.11	-0.08	-0.13	0.3	0.4	0.08	0.29	0.99	0.13	-0.51	-0.12
Non Current Assets Total	-0.09	0.78	-0.35	-0.6	-0.06	-0.15	-0.28	0.09	0.67	-0.52	-0.1		0.1	-0.1	0.79	0.22	0.03	0.35	-0.55	-0.64	-0.29	-0.6	-0.17	-0.67	0.24	0.71
Non Currrent Assets Other	-0.42	-0.18	-0.01	-0.12	-0.42	-0.38	0.04	0.45	0.06	-0.25	-0.46	0.1		-0.46	-0.2	0.41	0.03	0.1	0.07	-0.14	-0.07	-0.04	-0.43	0.19	0.16	0.19
Cash And Short Term Investments	0.99	0.11	0.23	0.13	0.99	0.49	-0.23	-1.0	-0.23	-0.11	1.0	-0.1	-0.46		-0.08	-0.11	-0.08	-0.13	0.3	0.4	0.08	0.29	0.99	0.13	-0.51	-0.12
Net Receivables	-0.11	0.92	-0.39	-0.5	-0.07	-0.01	-0.26	0.07	0.66	-0.19	-0.08	0.79	-0.2	-0.08		0.36	0.07	0.34	-0.7	-0.64	-0.28	-0.66	-0.17	-0.89	0.06	0.59
Common Stock Shares Outstanding	-0.07	0.24	0.3	0.25	-0.11	0.08	-0.6	0.1	-0.17	0.24	-0.11	0.22	0.41	-0.11	0.36		0.3	0.09	0.02	0.12	0.25	0.13	-0.09	-0.08	-0.56	0.11
Non Current Liabilities Total	-0.06	-0.01	0.41	0.33	-0.18	0.4	-0.16	0.08	-0.16	0.12	-0.08	0.03	0.03	-0.08	0.07	0.3		-0.24	0.05	0.12	0.84	0.23	-0.06	-0.02	-0.23	0.16
Inventory	-0.15	0.32	-0.07	-0.24	-0.11	-0.49	-0.05	0.13	0.37	-0.3	-0.13	0.35	0.1	-0.13	0.34	0.09	-0.24		-0.32	-0.37	-0.28	-0.46	-0.17	-0.32	0.2	0.49
Other Current Assets	0.4	-0.6	0.53	0.71	0.34	0.29	-0.24	-0.3	-0.8	0.51	0.3	-0.55	0.07	0.3	-0.7	0.02	0.05	-0.32		0.81	0.45	0.82	0.44	0.88	-0.49	-0.55
Other Stockholder Equity	0.45	-0.61	0.79	0.91	0.38	0.44	-0.46	-0.39	-0.98	0.55	0.4	-0.64	-0.14	0.4	-0.64	0.12	0.12	-0.37	0.81		0.6	0.93	0.5	0.82	-0.71	-0.71
Total Liab	0.12	-0.36	0.8	0.76	-0.01	0.48	-0.34	-0.08	-0.63	0.34	0.08	-0.29	-0.07	0.08	-0.28	0.25	0.84	-0.28	0.45	0.6		0.63	0.15	0.42	-0.5	-0.19
Property Plant And Equipment Gross	0.36	-0.69	0.71	0.83	0.28	0.45	-0.33	-0.29	-0.93	0.51	0.29	-0.6	-0.04	0.29	-0.66	0.13	0.23	-0.46	0.82	0.93	0.63		0.4	0.79	-0.59	-0.69
Total Current Assets	1.0	0.02	0.3	0.24	0.99	0.52	-0.26	-0.99	-0.34	-0.02	0.99	-0.17	-0.43	0.99	-0.17	-0.09	-0.06	-0.17	0.44	0.5	0.15	0.4		0.25	-0.57	-0.2
Short Term Debt	0.2	-0.82	0.59	0.72	0.15	0.09	-0.15	-0.13	-0.85	0.38	0.13	-0.67	0.19	0.13	-0.89	-0.08	-0.02	-0.32	0.88	0.82	0.42	0.79	0.25		-0.37	-0.61
Intangible Assets	-0.56	0.01	-0.67	-0.68	-0.49	-0.64	0.69	0.51	0.67	-0.41	-0.51	0.24	0.16	-0.51	0.06	-0.56	-0.23	0.2	-0.49	-0.71	-0.5	-0.59	-0.57	-0.37		0.42
Common Stock	-0.15	0.54	-0.32	-0.61	-0.13	-0.48	0.08	0.11	0.74	-0.63	-0.12	0.71	0.19	-0.12	0.59	0.11	0.16	0.49	-0.55	-0.71	-0.19	-0.69	-0.2	-0.61	0.42

Click cells to compare fundamentals

Bio Path Account Relationship Matchups

Bio Path fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.7M	16.5M	26.6M	16.0M	3.2M	3.1M
Other Current Liab	673K	881K	688K	801K	1.2M	1.3M
Total Current Liabilities	1.2M	1.2M	958K	1.7M	1.9M	2.0M
Total Stockholder Equity	21.1M	15.1M	25.5M	14.2M	441K	419.0K
Property Plant And Equipment Net	670K	519K	428K	356K	178K	344.7K
Net Debt	(20.0M)	(13.4M)	(23.5M)	(10.2M)	(939K)	(986.0K)
Retained Earnings	(56.3M)	(67.2M)	(77.7M)	(91.5M)	(107.6M)	(102.2M)
Accounts Payable	486K	100K	106K	667K	457K	479.9K
Cash	20.4M	13.8M	23.8M	10.4M	1.1M	999.4K
Non Current Assets Total	670K	519K	428K	356K	178K	169.1K
Non Currrent Assets Other	(13.4M)	288K	225K	158K	76K	79.8K
Cash And Short Term Investments	20.4M	13.8M	23.8M	10.4M	1.1M	999.4K
Common Stock Shares Outstanding	132.9K	192.4K	336.3K	363.8K	478K	292.6K
Liabilities And Stockholders Equity	22.7M	16.5M	26.6M	16.0M	3.2M	3.1M
Non Current Liabilities Total	330K	236K	153K	113K	873K	916.7K
Other Current Assets	788K	2.2M	2.4M	5.2M	2.0M	2.1M
Other Stockholder Equity	77.4M	82.3M	103.1M	105.7M	108.0M	113.4M
Total Liab	1.6M	1.4M	1.1M	1.8M	2.8M	2.9M
Property Plant And Equipment Gross	670K	519K	1.3M	1.3M	1.2M	1.3M
Total Current Assets	22.0M	16.0M	26.1M	15.6M	3.0M	2.9M
Common Stock	1K	4K	5K	7K	8K	950.0
Common Stock Total Equity	11K	1K	4K	5K	4.5K	4.3K
Net Tangible Assets	1.2M	21.1M	15.1M	25.5M	29.3M	30.7M
Retained Earnings Total Equity	(39.2M)	(47.7M)	(56.3M)	(67.2M)	(60.5M)	(57.5M)
Capital Surpluse	47.2M	49.0M	77.4M	82.3M	94.6M	99.4M
Property Plant Equipment	406K	303K	231K	428K	492.2K	282.1K
Accumulated Depreciation	(330K)	(592K)	(726K)	(798K)	(718.2K)	(682.3K)
Net Invested Capital	21.1M	15.1M	25.5M	14.2M	441K	419.0K
Net Working Capital	20.7M	14.8M	25.2M	13.9M	1.1M	1.1M

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Path's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(8.34)

Return On Assets

(1.40)

Return On Equity

(3.66)

The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Free Cash Flow Yield vs Pfcf Ratio Analysis

Free Cash Flow Yield vs Pfcf Ratio

Free Cash Flow Yield vs Pfcf Ratio Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Pfcf Ratio

Bio Path fundamental ratios Correlations

Bio Path Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bio Path fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Cash	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Other Stockholder Equity	- 0.98	Retained Earnings